Skip to main
STTK
STTK logo

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc. is strategically positioned in the biotechnology sector, focusing on innovative treatments for inflammatory diseases, with a notable program, SL-325, aimed at becoming a first-in-class DR3 antagonist antibody. The significant increase in biologics usage among patients with Crohn's Disease (from 22% to 44%) and Ulcerative Colitis (from 5% to 16%) between 2007 and 2015 demonstrates a growing market opportunity, suggesting that demand for effective treatments is on the rise. Additionally, the company's conservative projections for SL-325's sales growth reflect a positive outlook for substantial market share growth, driven by the ongoing demand for high-efficacy and safe therapeutic options in this expanding segment.

Bears say

Shattuck Labs Inc faces significant challenges in its development of therapies for inflammatory bowel disease (IBD), as evidenced by market growth and advanced therapy adoption being consistently underestimated since the launch of the first biologics. The company’s lead programs, including SL-325 and SL-425, carry inherent risks, such as potential ineffectiveness, high immunogenicity, or negative safety signals, which could impede their development and market adoption. Additionally, the reliance on clinical response metrics, such as the Crohn's Disease Activity Index (CDAI), further complicates the outcome predictions, contributing to uncertainty regarding the future viability of its product pipeline and overall financial outlook.

Shattuck Labs (STTK) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 2 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.